SHV Energy is looking for a full-time "Open Innovation Lead" | Apply now
Follow
More…

Covid-19 Innovation Challenges by Innoget

Hospital & Health Care • Innovation Intermediary • United Kingdom • 98 followers

Follow
More…

Is your organization promoting or looking for innovation or research initiatives to mitigate the Covid-19 outbreak? Email us at covid19@innoget.com to list them.

Latest Open Innovation Opportunities

  • Technology Offers (31)

Breathe free air of COVID-19 in indoor common areas

The Institute of Chemical Process Engineering of the University of Alicante has developed a system that allows the individual supply of disinfected air simultaneously to multiple users in closed spaces of common use. This s

Patents for licensing

Breathe free air of COVID-19 in indoor common areas
  • +6 months
  • Hide post

New use for an existing drug as antiviral agent against SARS-CoV-2 to prevent or/and treat COVID-19

CSIC has discovered a new use for an existing drug on the market as antiviral agent. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement.

Patents for licensing

New use for an existing drug as antiviral agent against SARS-CoV-2 to prevent or/and treat COVID-19
  • +6 months
  • Hide post

SARS-CoV-2 Targeted Libraries for offer

Protease-Oriented SARS-CoV-2 Library (1017 Compounds) - Developed by Virtual Receptor-Based Screening Using the Crystal Structure of the Basic SARS-CoV-2 Protease (PDB ID: 6LU7) ML (Machine Learning) SARS-target library (157

Innovative Products and Technologies

SARS-CoV-2 Targeted Libraries for offer
  • +6 months
  • Hide post

Viral RNA-dependent RNA Polymerases

Viral RNA-dependent RNA Polymerases (RdRPs) Targeted Library (1259 compounds) with predicted activity against viral RdRPs is offered. It has been carefully designed using machine learning (artificial neural networks and Bayes

Innovative Products and Technologies

Viral RNA-dependent RNA Polymerases
  • +6 months
  • Hide post

SARS-CoV-2 RNA-dependent RNA Polymerase Targeted Library

OtavaResearch Institute group presents SARS-CoV-2 RNA-dependent RNA Polymerase Targeted Library (1031 in-stock compounds with predicted activity against SARSCoV2 (RdRpp)).

Innovative Products and Technologies

SARS-CoV-2 RNA-dependent RNA Polymerase Targeted Library
  • +6 months
  • Hide post

SARS-CoV-2 Papain-like ProteaseTargeted Library

Using receptor based virtual screening OtavaResearchInstitute’s team designed the SARS-CoV-2 Papain-like Protease PLpro Targeted Library, which is contain 1058 stock compounds with predicted activity against this protease a

Innovative Products and Technologies

SARS-CoV-2 Papain-like ProteaseTargeted Library
  • +6 months
  • Hide post

SARS-CoV-2 NSP16 Targeted Library

SARS-CoV-2 2′-O-methyltransferase (NSP16) Targeted Library, which contains 1049 compounds with predicted activity against SARS-CoV-2 NSP16 is offered. The library has been designed with receptor-based virtual screening usin

Innovative Products and Technologies

SARS-CoV-2 NSP16 Targeted Library
  • +6 months
  • Hide post

SARS-CoV-2 Helicase Targeted Library

The offer SARS-CoV-2 Helicase (NSP13) Targeted Library, which contain 1170 compounds with predicted activity against this vital protein. The overall procedure included accurate flexible docking of Drug-like Green Collection i

Innovative Products and Technologies

SARS-CoV-2 Helicase Targeted Library
  • +6 months
  • Hide post

A Novel Therapeutic Approach Targeting Coronavirus Replication-Essential RNAs by Oligonucleotides

A Novel Therapeutic Approach Targeting Coronavirus Replication-Essential RNAs by Oligonucleotides. The research team plans to develop a drug to inhibit human SARS-CoV-2 replication. They will use comparative genomics to de

Innovative Products and Technologies

A Novel Therapeutic Approach Targeting Coronavirus Replication-Essential RNAs by Oligonucleotides
  • +4 weeks
  • Hide post

The Use of Chip Scale Photonics for the Advanced, and Efficient Detection of Viruses

The Use of Chip Scale Photonics for the Advanced, and Efficient Detection of Viruses Chip scale photonics technology is developing rapidly for diverse applications, from communication and computation to various types of se

Innovative Products and Technologies

The Use of Chip Scale Photonics for the Advanced, and Efficient Detection of Viruses
  • +4 weeks
  • Hide post

Active Masks with Virus Neutralizing Properties

Active Masks with Virus Neutralizing Properties Professors Willner and Pikarsky are developing masks and possible ventilation systems that will contain virus neutralizing properties. They have undertaken the development of

Innovative Products and Technologies

Active Masks with Virus Neutralizing Properties
  • +4 weeks
  • Hide post

Relieving Lung disease in COVID-19 Patients with Aerosols that Carry Viral Genes Inhibitors

Relieving Lung disease in COVID-19 Patients with Aerosols that Carry Viral Genes Inhibitors Step One: “Smart” micro - or nano-particles carrying inhibitors of the gene machinery in pathogens are developed. Step Two: I

Innovative Products and Technologies

Relieving Lung disease in COVID-19 Patients with Aerosols that Carry Viral Genes Inhibitors
  • +4 weeks
  • Hide post

5-MER Peptide to Ameliorate Coronavirus-Induced Inflammation of the Upper Respiratory Tract and Lungs

5-MER Peptide to Ameliorate Coronavirus-Induced Inflammation of the Upper Respiratory Tract and Lungs This study will test the hypothesis that treatment with a peptide comprising five units (5-MER), which is administered b

Innovative Products and Technologies

5-MER Peptide to Ameliorate Coronavirus-Induced Inflammation of the Upper Respiratory Tract and Lungs
  • +4 weeks
  • Hide post

High-Throughput Sequencing Methods to Test Samples

Highly parallel test for the presence of SARS-CoV-2 The currently used test for SARS-CoV2 virus uses molecular methods for detecting the presence of viral RNA sequences in subject samples. This is the approved gold standar

Innovative Products and Technologies

High-Throughput Sequencing Methods to Test Samples
  • +4 weeks
  • Hide post

Novel Activating Antibodies for Viral Treatment

Novel Activating Antibodies for Viral Treatment Various pathogens (bacteria and viruses as well) bind to specific cell adhesion molecule in order to inhibit the immune response and/or to infect the host cells. However,upon

Innovative Products and Technologies

Novel Activating Antibodies for Viral Treatment
  • +4 weeks
  • Hide post

Rapid Computational Screening of Natural Products for COVID-19 Anti-Viral Agents

Some edible compounds are potent antiviral agents and were tested successfully against SARS and MERS viruses. They hence provide an large source for rapid development and production of cure against COVID-19. These compounds a

Innovative Products and Technologies

Rapid Computational Screening of Natural Products for COVID-19 Anti-Viral Agents
  • +4 weeks
  • Hide post

Plant-based Diagnostic Kit to Detect Sick and Recovered SARS-CoV-2 Virus Patients

Genetically modified plant systems that allow identification of SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies Applications Preventing the spread of the epidemic Restoring economic activity by returning immune-positive, s

Innovative Products and Technologies

Plant-based Diagnostic Kit to Detect Sick and Recovered SARS-CoV-2 Virus Patients
  • +4 weeks
  • Hide post

Using Peptide Nucleic Acids (PNAs) as a Tool to Diagnose COVID-19

Using Peptide Nucleic Acids (PNAs) as a Tool to Diagnose COVID-19 We offer a fast and efficient diagnostic method which can be applied to a large amount of tests in a short time. Our method is based on a kit which identif

Innovative Products and Technologies

Using Peptide Nucleic Acids (PNAs) as a Tool to Diagnose COVID-19
  • +4 weeks
  • Hide post

Systematic Computational Drug Repositioning to Treat COVID-19

Systematic Computational Drug Repositioning to Treat COVID-19 The genetic revolution which has taken place in recent years brings new opportunities to the field of drug discovery & repositioning. Using advanced comparative

Innovative Products and Technologies

Systematic Computational Drug Repositioning to Treat COVID-19
  • +4 weeks
  • Hide post

Screening of Drugs to Inhibit Viral Infections

Our group has published a lot of work on the SARS Coronavirus. We were the first to characterize an important protein in the virus that has a very unusual structure and sequence (E protein). Moreover, this protein was unique

Innovative Products and Technologies

Screening of Drugs to Inhibit Viral Infections
  • +4 weeks
  • Hide post

A Unique Platform for Curing Coronavirus and Similar Lethal Diseases

A Unique Platform for Curing Coronavirus and Similar Lethal Diseases A Unique Platform for Curing Coronavirus and Similar Lethal Diseases Project ID : 47-2020-10878

Innovative Products and Technologies

A Unique Platform for Curing Coronavirus and Similar Lethal Diseases
  • +4 weeks
  • Hide post

Fooling the Virus: A Fusion Protein as Virus-Specific Therapeutic

Fooling the Virus: The Fusion protein as Virus-Specific Therapeutic An ACE2 A fusion protein of ACE2 with an Immunogenic Component Project ID : 47-2020-10877

Innovative Products and Technologies

Fooling the Virus: A Fusion Protein as Virus-Specific Therapeutic
  • +4 weeks
  • Hide post

Deciphering the Virus-Host Tango: Understanding network of interactions through evolution, structure, dynamics, and computational design

Deciphering the Virus-Host Tango: Understanding network of interactions through evolution, structure, dynamics, and computational designProject ID : 47-2020-10875

Innovative Products and Technologies

Deciphering the Virus-Host Tango: Understanding network of interactions through evolution, structure, dynamics, and computational design
  • +4 weeks
  • Hide post

Using Signature Genes to Detect Early-Stage Coronavirus and Predict Individual Outcomes

Using Signature Genes to Detect Early-Stage Coronavirus and Predict Individual Outcomes Project ID : 47-2020-10876 Test signature genes of host for non-invasive and early detection of Coronavirus infection, even before th

Innovative Products and Technologies

Using Signature Genes to Detect Early-Stage Coronavirus and Predict Individual Outcomes
  • +4 weeks
  • Hide post

Early warning system for detecting deterioration in post intensive care patients

In the UK 28% of deaths in patients treated on an Intensive Care Unit (ICU) occur after the patients return to the general ward. These patients often suffer late developing complications after initial successful treatment in

Innovative Products and Technologies

Early warning system for detecting deterioration in post intensive care patients
  • +1 month
  • Hide post

S-PACES. People and vehicle monitoring IoT system to control confinement and healthcare measures during COVID-19

People and vehicle monitoring IoT system to control confinement and healthcare measures during COVID-19. With this SmartCities Solution, the goal is to have a tool capable of knowing the movements of people and vehicles in

Innovative Products and Technologies

S-PACES. People and vehicle monitoring IoT system to control confinement and healthcare measures during COVID-19
  • +2 months
  • Hide post

Shimmer3 Bioimpedance Monitor - Monitoring HR, respiration rate and depth, and the increase in fluid in the lungs to triage and remotely monitor Covid-19 patients

Managing the huge influx of patients in hospitals is one of the most critical challenges of the current COVID-19 pandemic. Shimmer’s Bioimpedance Monitor has the potential to help manage this challenge by monitoring HR, res

Innovative Products and Technologies

Shimmer3 Bioimpedance Monitor - Monitoring HR, respiration rate and depth, and the increase in fluid in the lungs to triage and remotely monitor Covid-19 patients
  • +3 months
  • Hide post

COVID-19 Rapid Diagnostic Kit

Designing and developing vaccines, cures and diagnostic kits can be considered as the first priority for every country which is in the first line of fighting against coronavirus. Now there is only PCR test and IgG/IgM test fo

Innovative Products and Technologies

COVID-19 Rapid Diagnostic Kit
  • +4 months
  • Hide post

Expertise in molecular biology either experimentally or computationally

The Institut de Biotecnologia i de Biomedicina (IBB) was created in 1970 as a research institute of the Universitat Autònoma de Barcelona (UAB) to promote fundamental biological research. In the year 2000, the focus of resea

Research Services and Capabilities

Expertise in molecular biology either experimentally or computationally
  • +4 months
  • Hide post

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors

A series of small pharmacological molecules have been discovered to be potent and non-cytotoxic inhibitors of viral fusion. The inhibitors act on the non-virally encoded lipids in the virion envelope. These molecules are ri

Innovative Products and Technologies

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors
  • +4 months
  • Hide post

Alphanosos rapid discovery technology against COVID 19

Alphanosos’ AI guided rapid discovery technology, validated in antimicrobials and anticancer, is expected to develop within 3 weeks of experimental work with a virology partner an anti-COVID-19 treatment composed of a syner

Innovative Products and Technologies

Alphanosos rapid discovery technology against COVID 19
  • +4 months
  • Hide post

Latest News

Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting

Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting

Published on 17 September, 2020

--- This article was originally published on the press room portal at lilly.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- - Primary endpoint of viral load change from baseline at day 11 was met for one of three doses; consistent effects of viral reduction seen at earlier time points - Rate of hospitalizations and ER visits was 1.7 percent (5/302) for LY-CoV555 ...
  • +6 months
  • Hide post
NIH researchers investigate virulence of SARS-CoV-2 virus

NIH researchers investigate virulence of SARS-CoV-2 virus

Published on 25 June, 2020

--- This article was originally published by Samantha Black, PhD, The Science Advisory Board staff writer on the digital media scienceboard.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- What makes the SARS-CoV-2 virus so virulent? Researchers from the U.S. National Institutes of Health (NIH) analyzed the genomics of the virus -- and compared it to other coron...
  • +1 month
  • Hide post
Sexton, BioSpherix collaborate to support cell & gene therapy needs

Sexton, BioSpherix collaborate to support cell & gene therapy needs

Published on 25 June, 2020

--- This article was originally published by The Science Advisory Board staff writers on the digital media scienceboard.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- Sexton Biotechnologies is partnering with BioSpherix Medical on the final steps of downstream bioprocessing, fill-finish. Sexton's off-the-shelf fill system, the Sexton Biotechnologies AF-500, ...
  • +1 month
  • Hide post
Ideaya and GSK partner on synthetic lethality programs

Ideaya and GSK partner on synthetic lethality programs

Published on 25 June, 2020

--- This article was originally published by The Science Advisory Board staff writers on the digital media scienceboard.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- Ideaya Biosciences and GlaxoSmithKline (GSK) have formed a strategic partnership in the emerging oncology field of synthetic lethality. Synthetic lethality occurs when the combination of two or...
  • +1 month
  • Hide post
Lilly begins phase III trial for COVID-19 therapy

Lilly begins phase III trial for COVID-19 therapy

Published on 19 June, 2020

--- This article was originally published by The Science Advisory Board staff writers on the digital media scienceboard.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- Eli Lilly has enrolled patients in a phase III study to evaluate the efficacy and safety of baricitinib in hospitalized adults with COVID-19. Baricitinib, marketed by the company as Olumiant, i...
  • +1 month
  • Hide post
Are interferons helpful or harmful during SARS-CoV-2 infection?

Are interferons helpful or harmful during SARS-CoV-2 infection?

Published on 19 June, 2020

--- This article was originally published by Samantha Black, PhD, The Science Advisory Board staff writer on the digital media scienceboard.net. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- The host immune system produces a variety of regulatory molecules, including interferons (IFNs), during a response to viral infection. Although previously considered beneficial,...
  • +1 month
  • Hide post
Scanning for answers to a pandemic

Scanning for answers to a pandemic

Published on 11 June, 2020

--- This article was originally published by Bill Gates on the digital media gatesnotes.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- A new surveillance program in Seattle is detecting cases of COVID-19 and helping guide public health responses. In any fight, it’s important to know your enemy. Unfortunately, in our battle against COVID-19, there’s a lot ...
  • +1 month
  • Hide post
Covid-19 Vaccine Generates Immune Response

Covid-19 Vaccine Generates Immune Response

Published on 11 June, 2020

--- This article was originally published by Alan on the digital media sciencebusiness.technewslist.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- First results from a clinical trial testing a vaccine to protect against Covid-19 infections show the vaccine produces an immune response in healthy participants. The trial, conducted by National Institute of Allergy ...
  • +1 month
  • Hide post
Announcing the COVID-19 Therapeutics Accelerator

Announcing the COVID-19 Therapeutics Accelerator

Published on 05 May, 2020

--- This article was originally published by Mark Suzman on the digital media gatesfoundation.org. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- The first time I ever wrote about global health was an article on the looming AIDS crisis in my native South Africa. My piece for the Johannesburg Star in 1991 reported dire predictions from experts about the potential of...
  • +3 months
  • Hide post
31 questions and answers about COVID-19: My thoughts on what to do now and other topics

31 questions and answers about COVID-19: My thoughts on what to do now and other topics

Published on 05 May, 2020

--- This article was originally published on March 19, 2020, by Bill Gates on the digital media gatesnotes.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- Yesterday I did a Reddit Ask Me Anything session on COVID-19. As usual, Redditors asked a lot of smart questions, and it was a great opportunity to have a fact-based discussion about this pandemic and what we...
  • +3 months
  • Hide post
COVID-19 clean-up will threaten EU digital and green goals

COVID-19 clean-up will threaten EU digital and green goals

Published on 05 May, 2020

--- This article was originally published on April 21, 2020, by Éanna Kelly on the digital media sciencebusiness.net. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- EU regional commissioner says Europe should not ‘destroy path we’re on’, but accepts demand for future funding will be dominated by post-pandemic rebuilding The EU commissioner who oversees reg...
  • +3 months
  • Hide post
Global leaders unite to ensure everyone everywhere can access new vaccines, tests and treatments for COVID-19

Global leaders unite to ensure everyone everywhere can access new vaccines, tests and treatments for COVID-19

Published on 05 May, 2020

--- This article was originally published on April 24, 2020 on the digital media who.int. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- Unprecedented gathering of heads of government, institutions and industry cements commitment to accelerate development and delivery for all populations Heads of state and global health leaders today made an unprecedented commitm...
  • +3 months
  • Hide post
Open Innovation and Multiparty Cooperation in Biotechnology and Pharmaceuticals: Alternative Measures in Times of Public Emergency

Open Innovation and Multiparty Cooperation in Biotechnology and Pharmaceuticals: Alternative Measures in Times of Public Emergency

Published on 04 May, 2020

--- This article was originally published on April 20, 2020, by HERDEM Attorneys at Law on the digital media lexology.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- The race for finding a cure for COVID-19 continues, as more research centers, private enterprises and universities around the globe concentrate on finding an antiviral or vaccine against the virus o...
  • +3 months
  • Hide post
Open innovation for Covid-19 crisis

Open innovation for Covid-19 crisis

Published on 04 May, 2020

--- This article was originally published on April 21, 2020, by Dr. Sheetal Menon on the digital media forbesindia.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- There is a need for collective and coordinated scientific undertakings on a global scale to rapidly expedite the development pipeline for drugs, vaccines, and diagnostics “We need our collective k...
  • +3 months
  • Hide post
Q BioMed Partner Mannin Research Developing Potential Treatment for Patients Infected with Coronavirus and Other Infectious Diseases

Q BioMed Partner Mannin Research Developing Potential Treatment for Patients Infected with Coronavirus and Other Infectious Diseases

Published on 16 April, 2020

--- This article was originally published on April 2, 2020, by Financial Buzz on the digital media financialbuzz.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- – Preclinical data show unique platform addresses vascular leakage, which may support the health of patients during coronavirus infection – Platform has been awarded grants from Canada and Europe...
  • +3 months
  • Hide post
From Vaccines to Testing, M2D2 is ‘Laser-Focused’ on the Coronavirus

From Vaccines to Testing, M2D2 is ‘Laser-Focused’ on the Coronavirus

Published on 16 April, 2020

--- This article was originally published on March 3, 2020, by Ed Brennen on University of Massachusetts Lowell's media portal. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- The announcement came in late June 2018, just as many people were turning their attention to Fourth of July cookouts and summer vacation plans. The federal agency tasked with solving critica...
  • +3 months
  • Hide post
Franz Fayot launches new aid linked to the development and production of products in the fight against Covid-19 for an envelope of 30 million euros

Franz Fayot launches new aid linked to the development and production of products in the fight against Covid-19 for an envelope of 30 million euros

Published on 15 April, 2020

--- This article was originally published on April 4, 2020, by The Ministry of the Economy on Meco.gouvernement.lu. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- As part of the economic stabilization program, the Government Council approved on April 8 on a proposal from the Minister of the Economy, Franz Fayot, an aid scheme to support both industrial research proj...
  • +3 months
  • Hide post
Pitt and UPMC roll out revolutionary way to test COVID-19 drugs

Pitt and UPMC roll out revolutionary way to test COVID-19 drugs

Published on 15 April, 2020

--- This article was originally published on April 9, 2020, 5 p.m by David Templeton  post-gazette.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- The overriding question in treating COVID-19 is whether such drugs as hydroxychloroquine or remdesivir — or multiple other drugs in the research pipeline — will make a difference? So University of Pittsb...
  • +3 months
  • Hide post

Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

Published on 14 April, 2020

Issued: London, UK Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine  Candidate vaccine expected to enter clinical trials in the second half of 2020 and, if successful, to be available in the second half of 2021 Sanofi and GSK today announce that they have signed a letter of intent to enter into a collaboration to develop an adjuvanted vaccine for COVID-19, using innovative technology from both c...
  • +3 months
  • Hide post
Top Kitchenware Provider Lifetime Brands Talks Coronavirus And Open Innovation

Top Kitchenware Provider Lifetime Brands Talks Coronavirus And Open Innovation

Published on 12 April, 2020

--- This article was originally published on April 8, 2020, by Stephen Key on Forbes.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. ---- The cancelation and postponement of massive trade events like the international housewares show in Chicago and national hardware show in Las Vegas have resulted in many unanswered questions. At these one-of-a-kind annual meeting ...
  • +3 months
  • Hide post
Opinion: What is the role of innovation in COVID-19 response?

Opinion: What is the role of innovation in COVID-19 response?

Published on 12 April, 2020

------ This article was originally published on April 7, 2020, by  David Milestone  on Devex.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. ------ Crises generate a lot of energy that, if harnessed constructively, can be a great source of innovation. The COVID-19 response is producing inspiring innovative responses proving that, indeed, necessity is the mothe...
  • +3 months
  • Hide post
The Global Patent Race for a COVID-19 Vaccine

The Global Patent Race for a COVID-19 Vaccine

Published on 30 March, 2020

--- This article was originally published on March 24, 2020, by Rebeca Harasimowicz on the digital version of The National Law Review. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- As COVID-19 is causing chaos around the globe, the world’s largest economies are competing to be the first to find a cure to this new pandemic and taking measures to ensure that their...
  • +4 months
  • Hide post
Impact of the Corona crisis on startups & tech

Impact of the Corona crisis on startups & tech

Published on 26 March, 2020

OOn top of the human toll, the Corona crisis is an economic shock, unlike anything we’ve seen for a long time. Retail, mobility, and travel are especially hit. Other sectors are outperforming the market: food delivery, online groceries, telehealth, streaming, gaming and video conferencing. Zoom is now worth more than Uber. Should Lyft acquire its own food delivery business to weather the storm? Eventually, the recovery will come. Which sta...
  • +4 months
  • Hide post
Coronavirus will show VCs’ true colours

Coronavirus will show VCs’ true colours

Published on 25 March, 2020

--- This article was originally published on March 23, 2020, by Matt Clifford on Sifted.eu. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- Most of us in the startup community pride ourselves on knowing something about exponential growth. Even so, it’s been hard to take in how quickly coronavirus has changed the landscape in the last couple of weeks. Unfortunatel...
  • +4 months
  • Hide post
Innovation Imperatives from Covid-19

Innovation Imperatives from Covid-19

Published on 23 March, 2020

--- This article was originally published on March 18, 2020 by Henry Chesbrough, Contributor, at the online version of Forbes. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- With some delay, we humans are beginning to marshal our counter-attack against the coronavirus. Some nascent but promising developments across a number of areas are worth noting, for they sket...
  • +4 months
  • Hide post
The state of Open Innovation

The state of Open Innovation

Published on 23 March, 2020

--- This article was originally published on March 20, 2020 by Irving Wladawsky-Berger, at the online version of the Wall Street Journal. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes. --- Firms today recognize that there are more capabilities for innovation in the marketplace than what they can possibly create on their own. This open innovation model, the antithesis o...
  • +4 months
  • Hide post

About

Ahead of the current Coronavirus outbreak, Innoget is fully committed to contributing to mobilizing scientific and expert communities to find a real solution to the Covid-19 pandemic. Therefore, we're supporting worldwide calls and programs that could help in any aspects of the coronavirus crisis.

Is your organization promoting or looking for innovation or research initiatives to mitigate the Covid-19 outbreak? Email us at covid19@innoget.com to list them.

Channeled through Innoget's online open innovation network, initiatives in the health, virology, medicine, or novel technologies applied to human health, among others, are listed and disseminated to Innoget members -ranging from hospitals, research institutes, scientists, businesses, and public administrations- and innovation partners worldwide.

Contact person

Jordi Ràfols

CEO at Covid-19 Innovation Challenges by Innoget
https://www.innoget.com/group/covid-19-open-innovation-initiative
–
Hospital & Health Care
11-50 employees
Innovation Intermediary
2020
United Kingdom

About our Innovation Strategy

Innoget connects you and your team to 175,000+ decision-makers around the world, providing access to hundreds of innovation and research opportunities you will find nowhere else to solve actual challenges. Being the partner of choice for thousands of organizations to generate new projects connecting with verified partners, Innoget has become the reference for effective online open innovation and technology transfer due to its leading platform Innoget.com. Innoget.com provides integrated open innovation and technology transfer functionalities and services to both easily externalize and internationalize your scientific and technological offer, as well as to introduce you to hundreds of exclusive innovation needs published by our community of businesses.

Research areas (8)

Applications for HealthBiological SciencesMedicine, Human HealthClinical Research, TrialsMedical Research and 3 more

Latest Job Offers

Covid-19 Innovation Challenges by Innoget has't published any job offer yet

Latest Events

Covid-19 Innovation Challenges by Innoget hasn't published any Event yet

Related profiles

Innoget © 2021 Innoget